INTRODUCTION
Hemorrhoids are one of the most common gastrointestinal disorders seen by general practitioners. It has been estimated that they can occur at any age and can affect both men and women. [1] The natural evolution of hemorrhoids is benign in nature, but they tend to get worse over time, and therefore they should be treated as soon as it occurs. The term hemorrhoids (or piles) is used to describe the enlargement of the venous tissues of the anal region, which becomes infl amed or prolapsed. [2] The anal canal consists of three fi brovascular cushions that are supported within the anal canal by a connective tissue framework, which is important in providing a watertight seal to the anus. Hemorrhoids result from the hypertrophy of the hemorrhoidal plexus and pathological changes in the anal cushions. [3, 4] The degenerative effects of aging and regular straining during bowel movements may weaken the supporting tissues, producing a shearing force on the cushions, causing their descent and prolapse. The prolapsed cushions impair venous return, resulting in engorgement that may be further exacerbated by chronic straining during defecation, inadequate fi ber intake, and conditions such as pregnancy, that raise intraabdominal pressure. Bleeding from the engorged prolapsed hemorrhoid occurs as a result of localized mucosal trauma or infl ammation, which damages the underlying blood vessels. The anal cushions of patients with hemorrhoids show signifi cant pathological changes like abnormal venous dilatation, vascular thrombosis, degenerative process in the collagen fi bers and fi broelastic tissues, distortion and rupture of the anal subepithelial muscle. [5] The symptoms associated with hemorrhoids include rectal bleeding, perianal pain, discomfort, mucous discharge, perianal itching, and irritation. [3, 4, [6] [7] [8] Hemorrhoids are generally classifi ed according to their position relative to the dentate line. External hemorrhoids originate below this line and become symptomatic only when thrombosed. Internal hemorrhoids arise above the dentate line and are marked by bleeding and protrusion. [9] They can be further graded according to the degree of prolapse. [10, 11] Internal hemorrhoids that bleed but do not prolapse are designated as Grade I hemorrhoids; those that prolapse and reduce spontaneously (with or without bleeding) are second grade hemorrhoids; prolapsed hemorrhoids requiring manual reduction are Grade III hemorrhoids; and prolapsed hemorrhoids that cannot be reduced are Grade IV hemorrhoids.
Treatment options vary based on the degree and severity of symptoms. Management of hemorrhoids may be medical (prescribing high fi ber diet, antimotility agents, topical analgesics and corticosteroid creams for symptomatic relief, alternative/traditional medicine like oral fl avonoids), nonoperative (sclerotherapy, cryotherapy, rubber band ligation, infrared photocoagulation, etc.) or surgical (open, closed, or stapled hemorrhoidectomy). In many countries, 70-80% of the population use traditional medicine for primary health care. As per World Health Organization (WHO), 80% of about 4000 million inhabitants on this planet rely on plant medicines. [12] Traditional healthcare systems are known to have different treatment regimens for management of hemorrhoids. Ayurveda is one of the traditional health care systems prevalent and practiced widely in India and other countries. Indian Regulations permit use of traditional medicine under proprietary ayurvedic medicine licenses. The preparations are approved by the state regulatory bodies and marketed. Several qualifi ed ayurvedic physicians (~Vaidyas) practice traditional methods and use traditional medications for management of hemorrhoids. There are over half a million ayurvedic practitioners and over 800,000 registered traditional medicine practitioners in India. [13] Proanthocyanidins, present in various plant parts, comprising of catechins and epicatechins, have been reported with free radical scavenging, antioxidant, [14] [15] [16] [17] [18] antiinfl ammatory, antiallergic, and vasodilatory activity. [19, 20] Proanthocyanidins have been shown to inhibit the enzymes hyaluronidase, elastase, and collagenase, which degrade connective tissue structures leading to increased vascular permeability. [21, 22] Moreover low compliance associated with treatments such as diet and lifestyle changes, hydrotherapy and mechanical compression therapy, renders oral therapy as an attractive option. [15] Several studies have assessed the use of oral micronized, purifi ed fl avonoid fraction (MPFF) (Dafl on ® 500 mg), [23] [24] [25] [26] [27] and is one of the most commonly used treatment option for Grade 1 and Grade II hemorrhoids. [28] On the basis of above considerations and probable mechanisms of action, we planned to use a marketed herbal preparation, Roidosanal ® (as capsules; standardized to contain not less than 7% of total catechins and epicatechins). Both the above products possess similar active chemical entities (fl avonoids) and therefore assumed to have a similar mechanism of action. We conducted a pilot scale, open-labeled, multicentre study to determine the safety of Roidosanal ® capsules, and to compare its effi cacy against Dafl on ® 500 mg, in patients with hemorrhoids.
MATERIALS AND METHODS

Study design
This study was a multicentric, randomized, open labeled study conducted at three centers, namely, Mohinder Hospital, Batra Hospital and Research Center, and South End Clinic, in New Delhi from January 2009 to June 2010. The study was approved by an independent ethics committee. The study project was supported by Next Gen Pharma India Pvt. Ltd., New Delhi, India.
Participants
Patients of either gender, aged ≥18 years, with hemorrhoids confi rmed by proctoscopy, visiting the recruitment centers were enrolled in the study. All patients had given signed informed consent before examination. Any patient presenting with anal fi ssures along with hemorrhoids was also recruited. Patients diagnosed with bleeding hemorrhoids and having no other abnormal vital signs and symptoms were included in the study. Pregnant and lactating women, alcoholics, and patients currently using other antihemorrhoidal drugs or planning to undergo any surgical procedure for hemorrhoids were excluded from the study.
Intervention
The test product consisted of a processed herbal preparation, Roidosanal ® (By Next Gen Pharma India Pvt. Ltd.) and it was compared with Daflon ® 500 mg (By Serdia Pharmaceuticals (India) Pvt. Ltd.). Roidosanal ® is a processed preparation from a mixture of four herbs, that is, gum-resin from Commiphora molmol (50%), gum-resin from Gardenia spp. (16.6%) and infl orescence from Tagates erecta (16.7%), and Mesua ferrea (16.7%). It is formulated as capsules and standardized to contain not less than 7% of total catechins and epicatechins. The control preparation, Dafl on ® 500 mg contains micronized purifi ed fl avonoid extracts of rutaceae 500 mg, equivalent to 450 mg of diosmin, and 50 mg of hesperidine per tablet. Dafl on ® 500 mg is marketed in India for treatment of venous diseases, namely, chronic organic and functional venous defi ciency of lower limbs, varicose veins, sequelae of phlebitis, hemorrhoids, etc. [23] Test product and comparator for the study were supplied by the sponsor. Patients were randomized at the initial consultation visit to receive either of the two treatments, Roidosanal ® Caps (2 caps twice daily; Gr R) or Dafl on ® 500 mg Tabs (2 tablets daily; as per the recommended dosage in package insert of the product; Gr D), for 15 days. Compliance was ensured by project staff through regular phone calls and pill count at the end of treatment regimen. Patients were advised to restrict the amount of salt and spices in food. No laxatives or use of any other antihemorrhoidal drugs were allowed during the trial period.
Adverse events
All observed and reported adverse events regardless of treatment group or suspected causal relationship were recorded on the adverse events page of the case report proforma. Abnormal fi ndings and clinically signifi cant changes such as excessive pain and bleeding, abnormal local pain or itching were evaluated during clinical and physical examination.
Randomization and allocation concealment
Randomization was performed using permuted blocks of ten. The randomization list and numbered packing of intervention was carried out by a person not involved in the study. All the interventions and random numbers were packed in separate opaque envelopes. The interventions were dispensed in a serial fashion to the patients.
Study assessments
On visit 1, screening and randomization was done. This involved signed informed consent and enrolment of patients as per the inclusion and exclusion criteria. Demographics and medical history including previous history of hemorrhoids or any other chronic diseases was assessed. Proctologic examination was performed to assess the hemorrhoidal conditions, and then the patients were randomized. The investigational products were given to all patients for 15 days with instructions for administration. Each patient's condition was assessed telephonically on the 8 th day. On visit 2 (day 16) proctological examination was conducted again and it marked the end of treatment. However, the patients were followed-up, with visit 3 being the last visit, at the end of day 45. Tolerability of the interventions was evaluated subjectively by the investigator. Details of assessments done at each visit are explained below.
Proctoscopy was performed at baseline and end of treatment (16 th day) by the same proctoscopy surgeon. Proctologic assessment was performed in the left-lateral position by inspection of the anal verge of the anal canal by using a proctoscope. [29, 30] Parameters namely, grade (I, II, III, IV) and position of hemorrhoids (at one site, two sites or all three primary sites, i.e., 3 th day of study. Anal pain was also recorded at the same time points using a linear visual analogue pain score (VAS) (range 0-10, 0 = no pain and 10 = the worst possible pain). However, the VAS score was regrouped as 1-3 = mild pain, 4-6 = moderate, and 7-10 = severe pain. [31] 
Endpoints
The primary end points included change in "Grade" and "Position" of hemorrhoids, as measured using a proctoscope. Secondary end points included changes in hemorrhoidal signs and symptoms namely, bleeding, itching, pain, soiling, tenesmus, irritation after defecation, and constipation.
Sample size calculation and statistical assessment
Since this was the fi rst randomized study using Roidosanal ® , a pilot study was designed and therefore, sample size calculation was not done.
Mean ± standard deviation was computed for continuous variables. Frequencies and percentages were calculated for categorical data of all symptoms. Bivariate relationships between pair of variables were analyzed using Fisher's exact test and Chi-square test. The analysis was subjected further to intention-to-treat analysis. Analysis was performed for all the primary and secondary end points. For the purpose of analysis, patients who dropped out before the 45-day time point, their data were carried forward from their last assessment to be included in the fi nal analysis. A P value of 0.05 or less was considered statistically signifi cant and that of 0.001 or less was considered highly statistically signifi cant. The data were analyzed by using SPSS statistical software version 16.0 (Statistical Package for Social Sciences; SPSS Inc, Chicago, IL).
RESULTS
One hundred and twenty patients were screened, of whom 28 patients were excluded as they did not fulfi ll selection criteria and 19 patients voluntarily declined to be a part of the study. Out of 73 randomized patients, 37 patients (28:9 = Male: Female) received Roidosanal ® (Gr R) and 36 patients (29:7 = M: F) received Dafl on ® 500 mg (Gr D) in a controlled fashion as shown in Figure 1 . The mean age of patients in Gr R and Gr D was 36 and 32 years, respectively. A total of 73% in Gr R and 81% patients in Gr D had no history of pelvic surgery before the treatment. About 71% and 84% patients in Gr R and Gr D respectively, had no history of usage of medications for hemorrhoids. There were no signifi cant differences in baseline characteristics for age, gender, past history of hemorrhoids, and duration of hemorrhoids and with regard to other ano-rectal disorders, grade of hemorrhoids, pain, bleeding, itching, soiling, irritation after defecation, constipation, tenesmus, and hemoglobin. Patients were allocated in a controlled fashion, keeping the randomization unbiased. Twenty-two (59.5%) patients in Gr R and 15 (41.7%) patients in Gr D completed the study. No serious adverse events were reported with either of the two treatment regimens, gastrointestinal upset was observed in three patients in Gr D.
Response in ano-rectal conditions
The distribution of patients at baseline between the two groups in terms of ano-rectal conditions were comparable (P = 0.299; Table 1 ). Both Roidosanal ® (P < 0.001) and Dafl on ® 500 mg (P = 0.027) signifi cantly improved the ano-rectal conditions [ Table 1 ].
Severity of hemorrhoids (grade and position of hemorrhoids)
The percentage distribution of all patients with regard to site and grade is shown in Table 1 . Roidosanal ® and Dafl on ® 500 mg were equally effective in patients with Grade I and Grade II hemorrhoids. Roidosanal ® showed better effi cacy and faster resolution of signs and symptoms in patients with Grade III hemorrhoids. A signifi cantly higher number of patients with Grade III hemorrhoids improved in Gr R as compared with Gr D (six patients in Gr R vs 0 patients in Gr D; P value < 0.05; Binomial test; not shown in Table 1 ). This is an important aspect, as Grade III hemorrhoids, unlike Grade I and II hemorrhoids, do not usually present spontaneous improvement of the symptoms.
Symptoms associated with hemorrhoids Bleeding
Intergroup analysis revealed that both Dafl on ® 500 mg and Roidosanal ® were comparable in decreasing the extent and frequency of bleeding associated with hemorrhoids at all visits. Intragroup analysis showed that there were lesser no. of patients in Gr R with complaints of bleeding as compared with patients in Gr D on Day 8 (P = 0.004 vs P = 0.102, Figure 2 ). The number of patients complaining of bleeding decreased in both groups on Days 16 and 45, but did not reach statistical signifi cance. The frequency of bleeding [ Table 3 ] decreased signifi cantly in both groups on Day 8 (P = 0.050 and P = 0.046 in Gr R and Gr D respectively) as compared with baseline, however, the changes on Days 16 and 45 did not reach statistical signifi cance. This could be due to a smaller sample size owing to a pilot trial design.
Pain
There was signifi cant decrease in severity and frequency of ano-rectal pain in both groups on Days 8, 16, and 45 [ Figure 3 and Table 3 Figure 3 and Table 3 ].
Itching
Both Roidosanal ® and Daflon ® 500 mg were equally effective in relieving the itching symptom and reducing its frequency [ Tables 2 and 3 ]. The relief from itching was observed as early as on the 8 th day, lasting till the end of study. There was no signifi cant difference in the effi cacy of both products in relieving symptoms of itching, when compared against each other at all visits [ Tables 2 and 3] .
Soiling
Eight (21.6%) patients in Gr R and five (13.9%) patients in Gr D complained of soiling at baseline. However, both the products were able to provide relief from soiling immediately, and lasting till the end of treatment [ Tables 2 and 3 ].
Tenesmus
Intergroup analysis did not yield any signifi cant difference; both Roidosanal ® and Dafl on ® 500 mg were equally effective in relieving tenesmus symptom. Both the treatments improved the symptoms of tenesmus signifi cantly after 8 days of treatment [ Table 2 ].
Irritation after defecation
Intergroup analysis revealed a similar effi cacy of both treatments [ Table 2 ]. Intragroup analysis demonstrated that patients in both groups were relieved of the irritation after defecation symptom on Days 8, 16 , and 45 in a signifi cant manner as compared with baseline [ Table 2 ].
Constipation
Patients with history of constipation in Gr R were relieved signifi cantly on 8 th (P = 0.001), 16 th (P < 0.004), and 45
th Day (P < 0.025) as compared with baseline. Patients in Gr D showed signifi cant relief only on the 8 th day (P = 0.042; Table 2 ). The relief with Roidosanal ® was prompt, achieved within 8 days of treatment, and sustained till the end of treatment and follow-up visit.
Diarrhea
Two (5.4%) patients in Gr R and 1 (2.8%) patient in Gr D complained of diarrheal symptoms at baseline (P = 0.999). Diarrheal symptoms improved in two patients (one in Gr R and one in Gr D) after treatment.
Hemoglobin level
Mean hemoglobin level at baseline was found to be 12.52 and 12.54 g/dl in Gr R and Gr D, respectively. Hemoglobin levels slightly improved after treatment (12.69 g/dl in Gr R and 12.70 g/dl in Gr D); however, the change between the groups or within group was not signifi cant.
DISCUSSION
Though there is anecdotal evidence demonstrating the use of herbal medicines containing bioflavonoids in ano-rectal diseases, scientifi c studies in this fi eld are grossly inadequate. Herbal products are attracting attention in developed countries too, as an alternative to high cost modern drugs and associated side effects.
A comparative, open label trial in different grades of hemorrhoids, confi rmed by proctoscopy was conducted in a total of 73 patients at three centers in urban and semi-urban areas catering to varied population of socioeconomic status and educational levels. The selected patients were randomly allocated to two groups, namely, a group taking processed herbal preparation (Roidosanal ® ) or a popularly prescribed preparation (Dafl on ® 500 mg) available in Indian market. The characteristic signs and symptoms of hemorrhoids were scored for both groups at baseline, Therapeutic objectives in treatment of piles include shrinkage of piles mass, subsiding inflammation and preventing infection in the anal region, preventing bleeding from the rectum, relieving itching in the anal region, and relieving constipation as well. Of all the above, reduction in inflammation, bleeding, and pain bring immediate relief to the patient, and is of considerable importance to the treating physician. The study results showed that the Roidosanal ® was effective in ameliorating ano-rectal conditions and associated signs and symptoms of hemorrhoids. The current study, although with a limited sample size was able to demonstrate the superior effi cacy of Roidosanal ® over Dafl on ® 500 mg, in improving the ano-rectal symptoms in patients, particularly with Grade III hemorrhoids. Prompt resolution of bleeding symptom on the 8 th day was also observed with Roidosanal ® . Treatment with either therapies demonstrated a signifi cant response in Grade I and Grade II hemorrhoids, bleeding, pain, anal itching, soiling, and constipation. The study also demonstrates the importance of traditional medicine in the normal routine of a patient with hemorrhoids unless there is an absolute need for surgical intervention.
L i m i t a t i o n s o f t h e s t u d y i n c l u d e d a p i l o t design (no sample size calculation), open label design, and no central laboratory for biochemistry tests or proctoscopy.
CONCLUSION
Roidosanal
® was found to be equally effective as Dafl on ® 500 mg in improving ano-rectal conditions and associated signs and symptoms of hemorrhoids. There were no major adverse events associated with the use of either product. Treatment of patients with Grade I to Grade III hemorrhoids with preparations like Roidosanal ® or Dafl on ® 500 mg would be benefi cial and can be looked for. Further large and double-blind trials with proper statistical methods need to be conducted to confi rm the results.
